Casomed Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 23-12-2024
- Paid Up Capital ₹ 2.00 Cr
as on 23-12-2024
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
About Casomed Pharmaceuticals
The Corporate was formerly known as Casomed Pharmaceutical Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vatchala Kumaravelan and Kumaravelan Arunasre serve as directors at the Company.
- CIN/LLPIN
U51909TN2016PTC103944
- Company No.
103944
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Feb 2016
- Date of AGM
05 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Casomed Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vatchala Kumaravelan  | Director | 03-Feb-2016 | Current |
| Kumaravelan Arunasre | Additional Director | 17-Apr-2019 | Current |
Financial Performance of Casomed Pharmaceuticals.
Casomed Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Casomed Pharmaceuticals?
In 2017, Casomed Pharmaceuticals had a promoter holding of 41.50% and a public holding of 58.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sri Aruna Global Exim Private LimitedActive 5 years 24 daysVatchala Kumaravelan and Kumaravelan Arunasre are mutual person
Aruna Natural Stones Private LimitedActive 5 years 1 monthVatchala Kumaravelan and Kumaravelan Arunasre are mutual person
- Mother Care Global Health India Private LimitedActive 9 years 6 months
Vatchala Kumaravelan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Casomed Pharmaceuticals?
Casomed Pharmaceuticals has a workforce of 2 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Casomed Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Casomed Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
